{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:20:19Z","timestamp":1787840419016,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To determine myopic progression, axial length elongation, best-corrected visual acuity (BCVA), pupil dilation, and accommodation amplitude following 24 months of Atropine 0.01% usage among progressive myopic patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Fifty-one progressive myopic patients (age range, 3.5\u201317 years) were included in the present study. Fifteen patients were excluded due to loss to follow-up (eight patients) and Atropine complications (seven patients) and 36 patients continued therapy. Myopic progression, axial length, far and near BCVA, pupil diameter, and accommodation amplitude were measured at baseline examination and repeated every 6 months up to 2 years. All patients were recommended to instill one drop of Atropine 0.01% in each eye every night. Absolute success of therapy was defined as myopic progression \u22640.50 diopter (D) and axial length growth \u22640.2 mm per year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Mean myopic progression was 0.16 and 1.28 D and mean axial length change was 0.05 and 0.69 mm at months 12 and 24, respectively. Pupil dilation was 1.26 and 1.84 mm and accommodation reduction was 3.38 and 3.37 D at the same follow-ups, while BCVA was not changed. Absolute success rate for myopic progression control was 56.8% at 12 months and 70.8% at 24 months follow-up. In addition, the success rate in respect to axial length changes was 44.4% and 58.3% at the same time points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Atropine 0.01% can slow myopic progression and axial length elongation at least in 50% of myopic cases at 12- and 24-month follow-up with no significant complications. Therefore, Atropine therapy is recommended in cases of progressive myopia in children and teenagers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/joco.joco_344_22","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:06:24Z","timestamp":1729076784000},"page":"82-88","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Myopia Controlling using Low Dose Atropine Eye Drop"],"prefix":"10.4103","volume":"36","author":[{"given":"Zhale","family":"Rajavi","sequence":"first","affiliation":[{"name":"Negah Aref Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran"},{"name":"Department of Ophthalmology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran"},{"name":"Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahareh","family":"Kheiri","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Medicine and Dentistry, Western University, Ontario, Canada"},{"name":"Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourosh","family":"Sheibani","sequence":"additional","affiliation":[{"name":"Basir Eye Health Research Center, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamideh","family":"Sabbaghi","sequence":"additional","affiliation":[{"name":"Department of Optometry, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"R1-20241018","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/APO.0000000000000236","article-title":"Epidemiology of myopia","volume":"5","author":"Wu","year":"2016","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R2-20241018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)"},{"key":"R3-20241018","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/ICL.0000000000000499","article-title":"A review of current concepts of the etiology and treatment of myopia","volume":"44","author":"Cooper","year":"2018","journal-title":"Eye Contact Lens"},{"key":"R4-20241018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/ICL.0000000000000207","article-title":"Myopia control:A review","volume":"42","author":"Walline","year":"2016","journal-title":"Eye Contact Lens"},{"key":"R5-20241018","first-page":"575","article-title":"Preventing myopia","volume":"114","author":"Lagr\u00e8ze","year":"2017","journal-title":"Dtsch Arztebl Int"},{"key":"R6-20241018","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/OPX.0000000000000808","article-title":"Myopia control with bifocal contact lenses:A randomized clinical trial","volume":"93","author":"Aller","year":"2016","journal-title":"Optom Vis Sci"},{"key":"R7-20241018","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","article-title":"Efficacy comparison of 16 interventions for myopia control in children:A network meta-analysis","volume":"123","author":"Huang","year":"2016","journal-title":"Ophthalmology"},{"key":"R8-20241018","first-page":"CD004916","article-title":"Interventions to slow progression of myopia in children","author":"Walline","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-20241018","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/bs.pmbts.2015.05.005","article-title":"Scleral mechanisms underlying ocular growth and myopia","volume":"134","author":"Metlapally","year":"2015","journal-title":"Prog Mol Biol Transl Sci"},{"key":"R10-20241018","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on atropine for the treatment of myopia 2:Myopia control with atropine 0.01% eyedrops","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"key":"R11-20241018","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.oftal.2017.12.015","article-title":"Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness","volume":"93","author":"Diaz-Llopis","year":"2018","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"R12-20241018","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12886-020-01746-w","article-title":"Efficacy and safety of atropine to control myopia progression:A systematic review and meta-analysis","volume":"20","author":"Zhao","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"R13-20241018","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) study:A randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"R14-20241018","doi-asserted-by":"crossref","first-page":"22267","DOI":"10.1038\/s41598-021-01708-2","article-title":"Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression:A 2-year clinical trial","volume":"11","author":"Cui","year":"2021","journal-title":"Sci Rep"},{"key":"R15-20241018","doi-asserted-by":"crossref","first-page":"01081","DOI":"10.3389\/fphar.2020.01081","article-title":"Analysis of factors that may affect the effect of atropine 0.01% on myopia control","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"key":"R16-20241018","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/1120672121998960","article-title":"Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute","volume":"31","author":"N\u00e9meth","year":"2021","journal-title":"Eur J Ophthalmol"}],"container-title":["Journal of Current Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_344_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:22:27Z","timestamp":1787836947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_344_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/joco.joco_344_22","relation":{},"ISSN":["2452-2325"],"issn-type":[{"value":"2452-2325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2022-12-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}